Abstract
Background: The treatment of systemic sclerosis is a difficult challenge because of the present lack of drugs definitely proven to alter the overall course of the disease. Objective: To address the current guidelines and to analyze the perspectives opened by the availability of new drugs and the identification of previously unknown pathways. Methods: The statements on current treatment are based on recently developed EULAR recommendations. The perspectives reflect the opinion of the authors on emerging topics. Results/conclusion: The treatment of systemic sclerosis has improved in recent years because a number of drugs have been shown to influence single disease manifestations. The identification of previously unknown pathways might open the way for further developments.